This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoo, L. I. Articles by Yuan, J. Search for Related Content PubMed PubMed Citation Articles by Yoo, L. I. Articles by Yuan, J.

Pten Deficiency Activates Distinct Downstream Signaling Pathways in a Tissue-Specific Manner

Departments of ¹ Cell Biology and ² Pathology, Harvard Medical School, Boston, Massachusetts and ³ Department of Molecular and Medical Pharmacology, University of California Los Angeles School of Medicine, Los Angeles, California

Requests for reprints: Junying Yuan, Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115. Phone: 617-432-4170; Fax: 617-432-4177; E-mail: junying_yuan{at}hms.harvard.edu.

PTEN deficiency predisposes to a subset of human cancers, but the mechanism that underlies such selectivity is unknown. We have generated a mouse line that conditionally deletes Pten in urogenital epithelium. These mice develop carcinomas at high frequency in the prostate but at relatively low frequency in the bladder, despite early and complete penetrance of hyperplasia in both organs. Cell proliferation is initially high in the bladder of newborn Pten-deficient mice but within days is inhibited by p21 induction. In contrast, proliferation remains elevated in Pten-deficient prostate, where p21 is never induced, suggesting that p21 induction is a bladder-specific compensatory mechanism to inhibit proliferation caused by Pten deletion. Furthermore, the AKT/mammalian target of rapamycin growth pathway, which is highly activated in Pten-deficient prostate, is not activated in bladder epithelium. Our results reveal alternative downstream signaling pathways activated by Pten deficiency that lead to tissue-specific susceptibilities to tumorigenesis. (Cancer Res 2006; 66(4): 1929-39)

This article has been cited by other articles:

				D. Yao, C. L. Alexander, J. A. Quinn, W.-C. Chan, H. Wu, and D. A. Greenhalgh Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21WAF-induced differentiation triggered by GSK3{beta} inactivation and reduced AKT activity J. Cell Sci., May 15, 2008; 121(10): 1758 - 1769. [Abstract] [Full Text] [PDF]

				C.-H. Kwon, D. Zhao, J. Chen, S. Alcantara, Y. Li, D. K. Burns, R. P. Mason, E. Y.-H. P. Lee, H. Wu, and L. F. Parada Pten Haploinsufficiency Accelerates Formation of High-Grade Astrocytomas Cancer Res., May 1, 2008; 68(9): 3286 - 3294. [Abstract] [Full Text] [PDF]

				T. A. Johnson, S. Tsutsui, and F. R. Jirik Antigen-Induced Pten Gene Deletion in T Cells Exacerbates Neuropathology in Experimental Autoimmune Encephalomyelitis Am. J. Pathol., April 1, 2008; 172(4): 980 - 992. [Abstract] [Full Text] [PDF]

				C. Wu and J. Huang Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Is Essential for Neuroendocrine Differentiation of Prostate Cancer J. Biol. Chem., February 9, 2007; 282(6): 3571 - 3583. [Abstract] [Full Text] [PDF]

				H. Tsuruta, H. Kishimoto, T. Sasaki, Y. Horie, M. Natsui, Y. Shibata, K. Hamada, N. Yajima, K. Kawahara, M. Sasaki, et al. Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients. Cancer Res., September 1, 2006; 66(17): 8389 - 8396. [Abstract] [Full Text] [PDF]

				A. Mirmohammadsadegh, A. Marini, S. Nambiar, M. Hassan, A. Tannapfel, T. Ruzicka, and U. R. Hengge Epigenetic Silencing of the PTEN Gene in Melanoma. Cancer Res., July 1, 2006; 66(13): 6546 - 6552. [Abstract] [Full Text] [PDF]